---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-102855"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2021-08-10T23:59:59+00:00"
generated_at: "2026-06-29T16:57:28.542711+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics appoints Mark Velleca to Board of Directors

## Summary
- Appointed Mark Velleca, M.D., Ph.D. as Class I director effective August 9, 2021.
- Determined independent under Nasdaq listing standards; not appointed to any committees initially.
- Will receive standard non-employee director compensation, including initial equity award per company policy.
- Velleca brings over 20 years biotech experience; previously CEO of G1 Therapeutics (led from Series A to FDA approval).
- No transactions with company requiring disclosure; selected per Board recommendation.

## SEC filing metadata
- accession: 0001104659-21-102855
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2021-08-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465921102855/0001104659-21-102855-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465921102855/tm2124656d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-102855
- JSON: https://secwatch.observer/filing/0001104659-21-102855.json
- Plain text: https://secwatch.observer/filing/0001104659-21-102855.txt

## Key facts
- Executive change
  Mark Velleca was appointed as Class I Director at Black Diamond Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: appointed Mark Velleca, M.D., Ph.D. to serve on the Board as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465921102855/0001104659-21-102855-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.